CD63 and prostate carcinoma: We previously developed a similar assay to detect and quantify plasma exosomes expressing Rab5B/CD63 or Rab5B/caveolin plasma exosomes and demonstrated that CD63+ exosomes or caveolin-1+ exosomes were significantly increased in melanoma and prostate cancer patients as compared to healthy donors (61, 62).